Beam Therapeutics Inc (NASDAQ: BEAM) kicked off on Monday, down -3.22% from the previous trading day, before settling in for the closing price of $26.39. Over the past 52 weeks, BEAM has traded in a range of $20.84-$49.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 54121.88%. While this was happening, its average annual earnings per share was recorded -174.09%. With a float of $72.58 million, this company’s outstanding shares have now reached $82.56 million.
The extent of productivity of a business whose workforce counts for 436 workers is very important to gauge. In terms of profitability, gross margin is 93.75%, operating margin of -52.25%, and the pretax margin is -40.67%.
Beam Therapeutics Inc (BEAM) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Beam Therapeutics Inc is 12.35%, while institutional ownership is 81.91%. The most recent insider transaction that took place on Jan 02 ’25, was worth 30,628. In this transaction Chief Legal Officer of this company sold 1,241 shares at a rate of $24.68, taking the stock ownership to the 102,968 shares. Before that another transaction happened on Jan 02 ’25, when Company’s SVP, Finance and Treasurer sold 1,117 for $24.68, making the entire transaction worth $27,568. This insider now owns 43,814 shares in total.
Beam Therapeutics Inc (BEAM) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -174.09% per share during the next fiscal year.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Take a look at Beam Therapeutics Inc’s (BEAM) current performance indicators. Last quarter, stock had a quick ratio of 5.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.76, a number that is poised to hit -1.27 in the next quarter and is forecasted to reach -4.79 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
The latest stats from [Beam Therapeutics Inc, BEAM] show that its last 5-days average volume of 1.44 million was superior to 1.33 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 46.70%. Additionally, its Average True Range was 1.83.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 39.49%, which indicates a significant increase from 31.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.53% in the past 14 days, which was lower than the 67.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.42, while its 200-day Moving Average is $25.42. Now, the first resistance to watch is $26.23. This is followed by the second major resistance level at $26.92. The third major resistance level sits at $28.16. If the price goes on to break the first support level at $24.30, it is likely to go to the next support level at $23.06. Assuming the price breaks the second support level, the third support level stands at $22.37.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
The company with the Market Capitalisation of 2.11 billion has total of 82,806K Shares Outstanding. Its annual sales at the moment are 377,710 K in contrast with the sum of -132,530 K annual income. Company’s last quarter sales were recorded 14,270 K and last quarter income was -96,670 K.
